Analyst firms · Barclays · TDOC
Barclays TDOC price target and rating history
Teladoc Health Inc. (TDOC) · Health Care
Barclays rates Teladoc Health Inc. (TDOC) Equal Weight with a $8.50 price target, as of its latest action on Dec 9, 2025. It has published 4 rating actions on TDOC since October 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a TDOC price target in the last 12 months, the median target is $8.50. Barclays's target matches it.
- Current rating
- Equal Weight
- Price target
- $8.50
- Median target, all firms
- $8.50
- Actions on TDOC
- 4
Barclays price target on TDOC
Every Barclays rating on TDOC
- Dec 9, 2025
- Jan 3, 2024
- Feb 23, 2022
- Oct 28, 2021
How other firms rate TDOC
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Sell | Nov 2, 2026 | |
| Deutsche Bank | Buy | $11 | Mar 10, 2026 |
| BofA Securities | Buy | $7 | Feb 26, 2026 |
| Barclays | Equal Weight | $8.50 | Dec 9, 2025 |
Questions about Barclays and TDOC
- What is Barclays's price target for TDOC?
- Barclays's latest stated price target for Teladoc Health Inc. (TDOC) is $8.50, from its action on Dec 9, 2025.
- What is Barclays's rating on TDOC?
- Barclays rates TDOC Equal Weight, a neutral rating, as of Dec 9, 2025.
- When did Barclays last change its view on TDOC?
- On Dec 9, 2025, Barclays starts coverage at Equal Weight, price target $8.50.
- How does Barclays's TDOC target compare with other analysts?
- Across 3 firms with a TDOC price target in the last 12 months, the median target is $8.50. Barclays's target matches it.
More TDOC rating histories
- Argus Research4
- Deutsche Bank4
- BofA Securities4
- Goldman Sachs4
- Jefferies3
- Leerink Partners7
- Guggenheim4
- KeyBanc Capital Markets3
- Needham4
- Wells Fargo3
- Citigroup3
- Credit Suisse4
- Piper Sandler3
- Oppenheimer4
All Barclays ratingsTDOC news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.